Ortin Global Limited (NSE:ORTINGLOBE)
14.75
-0.35 (-2.32%)
Sep 24, 2026, 3:10 PM IST
Ortin Global Revenue
Ortin Global had revenue of 160.00K INR in the quarter ending June 30, 2026, a decrease of -59.80%. This brings the company's revenue in the last twelve months to 356.00K, down -79.47% year-over-year. In the fiscal year ending March 31, 2026, Ortin Global had annual revenue of 1.08M, down -68.35%.
Revenue (ttm)
356.00K
Revenue Growth
-79.47%
P/S Ratio
349.47
Revenue / Employee
44.50K
Employees
8
Market Cap
124.41M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 1.08M | -2.34M | -68.35% |
| Mar 31, 2025 | 3.43M | -18.84M | -84.61% |
| Mar 31, 2024 | 22.26M | -38.08M | -63.11% |
| Mar 31, 2023 | 60.34M | -21.97M | -26.69% |
| Mar 31, 2022 | 82.31M | 633.62K | 0.78% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Valiant Laboratories | 3.06B |
| Amanta Healthcare | 2.91B |
| Balaxi Pharmaceuticals | 2.80B |
| Bafna Pharmaceuticals | 1.43B |
| Alpa Laboratories | 1.11B |
| Par Drugs and Chemicals | 1.09B |
| Vaishali Pharma | 1.08B |
| Brooks Laboratories | 831.87M |